Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
Chad Landmon, Ross Blau, and Gulrukh Haroon*
Life Sciences IP Review
Axinn partner Chad Landmon and associates Ross Blau and Gulrukh Haroon co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.
*Not yet admitted to the New York Bar